Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe-Reference-Cited by-同舟云学术

Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe

Published:2020-12-11 Issue:3 Volume:23 Page:556-567
ISSN:1524-6175
Container-title:The Journal of Clinical Hypertension
language:en
Short-container-title:J Clin Hypertens

Author:

Lin Donna S.‐H.¹^ORCID,Wang Tzung‐Dau¹²^ORCID,Buranakitjaroen Peera³,Chen Chen‐Huan⁴⁵⁶^ORCID,Cheng Hao‐Min⁴⁵⁶⁷^ORCID,Chia Yook Chin⁸⁹^ORCID,Sukonthasarn Apichard¹⁰^ORCID,Tay Jam Chin¹¹^ORCID,Teo Boon Wee¹²^ORCID,Turana Yuda¹³^ORCID,Wang Ji‐Guang¹⁴^ORCID,Kario Kazuomi¹⁵^ORCID,

Affiliation:

1. Department of Internal Medicine Cardiovascular Center and Division of Cardiology National Taiwan University Hospital Taipei City Taiwan

2. Department of Internal Medicine Division of Hospital Medicine National Taiwan University Hospital Taipei City Taiwan

3. Department of Medicine Division of Hypertension Faculty of Medicine Siriraj Hospital Mahidol University Bangkok Thailand

4. Institute of Public Health and Community Medicine Research Center National Yang‐Ming University School of Medicine Taipei Taiwan

5. Department of Medicine Division of Cardiology Taipei Veterans General Hospital Taipei Taiwan

6. Faculty of Medicine National Yang‐Ming University School of Medicine Taipei Taiwan

7. Department of Medical Education Center for Evidence‐based Medicine Taipei Veterans General Hospital Taipei Taiwan

8. Department of Medical Sciences School of Healthcare and Medical Sciences Sunway University Bandar Sunway Selangor Darul Ehsan Malaysia

9. Department of Primary Care Medicine Faculty of Medicine University of Malaya Kuala Lumpur Malaysia

10. Department of Internal Medicine Cardiology Division Faculty of Medicine Chiang Mai University Thailand

11. Department of General Medicine Tan Tock Seng Hospital Singapore Singapore

12. Department of Medicine Division of Nephrology Yong Loo Lin School of Medicine Singapore Singapore

13. School of Medicine and Health Sciences Atma Jaya Catholic University of Indonesia Jakarta Indonesia

14. Department of Hypertension Centre for Epidemiological Studies and Clinical Trials the Shanghai Institute of HypertensionShanghai Key Laboratory of HypertensionRuijin HospitalShanghai Jiaotong University School of Medicine Shanghai China

15. Department of Medicine Division of Cardiovascular Medicine Jichi Medical University School of Medicine Tochigi Japan

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jch.14120

Reference66 articles.

1. An evaluation of the fixed-dose combination sacubitril/valsartan for the treatment of arterial hypertension

2. Systolic hypertension: an increasing clinical challenge in Asia

3. Current status of home blood pressure monitoring in Asia: Statement from the HOPE Asia Network

4. Prevalence, treatment, control and monitoring of hypertension: a nationwide community‐based survey in Taiwan, 2017;Pan H‐Y;Acta Cardiol Sin,2020

5. Will we ever use angiotensin receptor neprilysin inhibition (ARNi) for the treatment of hypertension?

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of the effects of angiotensin receptor–neprilysin inhibitors and thiazide diuretic/renin–angiotensin system inhibitor combination therapy in hypertensive patients: a retrospective cohort study;Journal of Human Hypertension;2023-07-24

2. Twenty‐Four‐Hour Blood Pressure‐Lowering Efficacy of Sacubitril/Valsartan Versus Olmesartan in Japanese Patients With Essential Hypertension Based on Nocturnal Blood Pressure Dipping Status: A Post Hoc Analysis of Data From a Randomized, Double‐Blind Multicenter Study;Journal of the American Heart Association;2023-04-18

3. Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction;Frontiers in Cardiovascular Medicine;2023-01-13

4. Dose-dependent reduction of blood pressure by angiotensin receptor-neprilysin inhibitor: A network meta-analysis;Research in Cardiovascular Medicine;2023

5. Cost Effectiveness of the First‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting;PharmacoEconomics;2022-09-08